Orchard Therapeutics is a holding company. Through its subsidiaries, Co. is a gene therapy company focused on the development of potentially curative gene therapies. Co.'s programs focused on neurodegenerative disorders consist of its commercial program approved in Europe, Libmeldy (OTL-200) for metachromatic leukodystrophy, two clinical proof of concept-stage programs, OTL-203 for mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, and three preclinical programs, OTL-202 for mucopolysaccharidosis type IIIB, OTL-204 for frontotemporal dementia with progranulin mutations and OTL-205 for amyotrophic lateral sclerosis. The ORTX average annual return since 2018 is shown above.
The Average Annual Return on the ORTX average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ORTX average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ORTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ORTX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
